Literature DB >> 15289937

TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells.

P Secchiero1, C Zerbinati, E Rimondi, F Corallini, D Milani, V Grill, G Forti, S Capitani, G Zauli.   

Abstract

Human and rat primary sub-cultured vascular smooth muscle cells (VSMCs) showed clear expression of the death receptors TRAIL-R1 and TRAIL-R2; however, recombinant soluble TRAIL did not induce cell death when added to these cells. TRAIL tended to protect rat VSMCs from apoptosis induced either by inflammatory cytokines tumor necrosis factor-alpha + interleukin-1beta + interferon-gamma or by prolonged serum withdrawal, and promoted a significant increase in VSMC proliferation and migration. Of note, all the biological effects induced by TRAIL were significantly inhibited by pharmacological inhibitors of the ERK pathway. Western blot analysis consistently showed that TRAIL induced a significant activation of ERK1/2, and a much weaker phosphorylation of Akt, while it did not affect the p38/MAPK pathway. Taken together, these data strengthen the notion that the TRAIL/TRAIL-R system likely plays a role in the biology of the vascular system by affecting the survival, migration and proliferation of VSMCs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289937     DOI: 10.1007/s00018-004-4197-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  49 in total

1.  B lymphocytes are resistant to death receptor 5-induced apoptosis.

Authors:  Roslyn N Crowder; Hong Zhao; W Winn Chatham; Tong Zhou; Robert H Carter
Journal:  Clin Immunol       Date:  2011-01-28       Impact factor: 3.969

2.  TRAIL shows potential cardioprotective activity.

Authors:  Barbara Toffoli; Stella Bernardi; Riccardo Candido; Serena Zacchigna; Bruno Fabris; Paola Secchiero
Journal:  Invest New Drugs       Date:  2011-01-04       Impact factor: 3.850

3.  Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production.

Authors:  Vera Levina; Adele M Marrangoni; Richard DeMarco; Elieser Gorelik; Anna E Lokshin
Journal:  Exp Cell Res       Date:  2008-01-16       Impact factor: 3.905

4.  Soluble TNF-related apoptosis induced ligand (sTRAIL) is augmented by Post-Conditioning and correlates to infarct size and left ventricle dysfunction in STEMI patients: a substudy from a randomized clinical trial.

Authors:  André Luz; Mário Santos; Rui Magalhães; José Carlos Oliveira; Ana Pacheco; João Silveira; Sofia Cabral; Severo Torres; Adelino F Leite-Moreira; Henrique Carvalho
Journal:  Heart Vessels       Date:  2016-05-26       Impact factor: 2.037

5.  Muscle-derived TRAIL negatively regulates myogenic differentiation.

Authors:  Dongwook Kim; Nilmani Singh; Rachel J Waldemer-Streyer; Mee-Sup Yoon; Jie Chen
Journal:  Exp Cell Res       Date:  2020-07-06       Impact factor: 3.905

6.  Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells.

Authors:  Kirsten Q T Nguyen; Ping Olesen; Thomas Ledet; Lars Melholt Rasmussen
Journal:  Endocrine       Date:  2007-09-29       Impact factor: 3.633

Review 7.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

8.  Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts.

Authors:  Paola Secchiero; Sonia Zorzet; Claudio Tripodo; Federica Corallini; Elisabetta Melloni; Lorenzo Caruso; Raffaella Bosco; Sabrina Ingrao; Barbara Zavan; Giorgio Zauli
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

9.  Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.

Authors:  Jing Xu; Jun-Ying Zhou; Wei-Zen Wei; Gen Sheng Wu
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

Review 10.  TNF superfamily: a growing saga of kidney injury modulators.

Authors:  Maria D Sanchez-Niño; Alberto Benito-Martin; Sara Gonçalves; Ana B Sanz; Alvaro C Ucero; Maria C Izquierdo; Adrian M Ramos; Sergio Berzal; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Mediators Inflamm       Date:  2010-10-04       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.